Lung Diseases, Interstitial

18 treatments and conditions followed through the public trial records. Not medical advice. How a status is set

Lists the pairs whose condition is this category or one beneath it. A category is not a diagnosis and not advice.

Broader: Lung Diseases

Narrower: Idiopathic Pulmonary Fibrosis 7, Pulmonary Fibrosis 9

Treatments and conditions

Lung Diseases, Interstitial
Treatment and conditionWhere it standsTrials
Anti Thymocyte Globulin + GM-CSF + Total Body Irradiation + ALEMTUZUMAB + RITUXIMAB + HUMAN IMMUNOGLOBULIN G + Cyclophosphamide + THIOTEPA + Mesna for lung diseases, interstitialPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Azithromycin 250 mg x3/week (3 tablets/week) + Hydroxychloroquine + Prednisone for lung diseases, interstitialTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
BC006 for idiopathic pulmonary fibrosisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Belimumab for lung diseases, interstitialPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Belumosudil 200 mg QD for pulmonary fibrosisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Bersiporocin for idiopathic pulmonary fibrosisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
CAL101 for idiopathic pulmonary fibrosisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Caspofungin for lung diseases, interstitialPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Colchicine 0.5 mg for pulmonary fibrosisPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
COVID-19 CONVALESCENT PLASMA for lung diseases, interstitialTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
Dry Powder Inhaler + inhaled mosliciguat for lung diseases, interstitialPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
HB0056 for idiopathic pulmonary fibrosisTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
HSK44459 for idiopathic pulmonary fibrosisTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Rentosertib for idiopathic pulmonary fibrosisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
ROC-101 for lung diseases, interstitialPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Simultaneous-Integrated Boost Intensity-Modulated Radiation Therapy + Volume Modulated Arc Therapy + NIVOLUMAB + IPILIMUMAB for lung diseases, interstitialPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Taladegib for idiopathic pulmonary fibrosisPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Tulisokibart for lung diseases, interstitialPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1

Categories are from Medical Subject Headings (MeSH), U.S. National Library of Medicine, courtesy of the U.S. National Library of Medicine: MeSH. They may not reflect the most current data available from NLM. NLM does not endorse this site.